SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SCHAUMBURG, Ill., March 23, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Sean Brynjelsen as Executive Vice President, Business Development. In this newly created role, Mr. Brynjelsen will develop and execute a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. Mr. Brynjelsen will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
Mr. Brynjelsen joins Sagent to lead the third objective of our “Triple E” growth strategy to execute on strategic M&A transactions to advance our growth and profitability, said Allan Oberman, chief executive officer of Sagent. “Sean has extensive experience in pharmaceutical transactions, strategic planning and product licensing/development, which makes him a great addition to our executive leadership team. This newly created position, in conjunction with the addition of our EVP of Global Operations earlier this quarter, fulfills our commitment to strengthen the leadership of Sagent and support the acceleration of our ability to execute on our growth strategy.”
Mr. Brynjelsen has over 20 years of transactional experience in the pharmaceutical industry with companies including Akorn, Hospira and Baxter. Most recently, he served as Senior Vice President, Global Business Development for Akorn where he completed over one hundred transactions including the acquisition of over 25 products contributing greater than $300 million of annual revenue. He earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in BioChemistry from the University of Illinois.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605
